Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972719 · ClinicalTrials.gov registry record · NA
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
A NA study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06972719 is a NA study of BRCA1 Mutation and BRCA2 Mutation that is actively recruiting participants, run by Duke University. The registered enrollment target is 50 participants, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06972719, a NA study of BRCA1 Mutation and BRCA2 Mutation, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Conditions Studied
Interventions
- BEHAVIORAL Experimental Arm
- BEHAVIORAL SOC Arm
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972719
The ClinicalTrials.gov registry entry for NCT06972719 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 2 interventions - of which Experimental Arm is the first listed.
NCT06972719 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06972719 about?
NCT06972719 is a clinical study titled "Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy". The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
What is the current status of trial NCT06972719?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-09-30. Estimated completion is 2026-12-31.
What conditions does trial NCT06972719 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT06972719?
The interventions under investigation include: Experimental Arm (BEHAVIORAL), SOC Arm (BEHAVIORAL).
Who is sponsoring clinical trial NCT06972719?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972719 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
FaCT Trial (Facilitated Cascade Testing Trial)
RECRUITING · NA
-
Decision Support for BRCA Testing in Ethnically Diverse Women
COMPLETED · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.